Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752924 | 0.82 | DRD2 (0.35) | KMT2AMEN1CYP1A2CYP2C19DRD2 | |
| SCHEMBL17902635 | 0.75 | MEN1 (0.39) | KMT2AMEN1SLC40A1CYP1A2CA12 | |
| SCHEMBL24089933 | 0.74 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL29657671 | 0.71 | KMT2A (0.64) | KMT2AMEN1CYP1A2DRD2DRD3 | |
| SCHEMBL255964 | 0.71 | KMT2A (0.64) | KMT2AMEN1CYP1A2DRD2DRD3 | |
| SCHEMBL9252901 | 0.69 | DPP8 (0.41) | SLC40A1TIPARPDPP8DPP9FFAR4 | |
| SCHEMBL9256008 | 0.68 | DPP8 (0.40) | SLC40A1TIPARPDPP8DPP9 | |
| SCHEMBL7424121 | 0.67 | — | — | |
| SCHEMBL19152905 | 0.67 | KMT2A (0.32) | KMT2AMEN1HTR3EHTR3BHTR3A | |
| SCHEMBL8348677 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4206184-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | KMT2A 1451/4885MEN1 1679/4885SLC40A1 1436/4885 |
| US-20230312474-A1 | PHENOL DERIVATIVE | TYR, NCOR1, BET1 | KMT2A 356/4885MEN1 1330/4885SLC40A1 1178/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | KMT2A 967/4885MEN1 1282/4885SLC40A1 1929/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | KMT2A 967/4885MEN1 1282/4885SLC40A1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.